Global SingleCell Genome Sequencing Market Overview
Single-Cell Genome Sequencing Market size was valued at about USD 2.6 Billion in 2024 and expected to grow at CAGR of 16.9% to extend a value of USD 10.8 Billion by 2034
Single-cell genome sequencing is a technique used to study the sequence information with optimized next-generation sequencing technologies from a single cell. Moreover, single-cell genome arises as a powerful set of technology which helps to examine rare cells and explaining complex populations. Furthermore, single-cell genome sequencing has diverse application in cancer research, immunology, neurology, microbiology, Germline Transmission, Embryogenesis, Organogenesis, development, and tissue mosaicism. Hence, owing to its broad application in the biology field, the global single-cell genome sequencing may gain more share value within the forecast period.
For More Report Details, Download Free Sample PDF
Global SingleCell Genome Sequencing Market Drivers & Restraints
Prevalence of diseases
As of now, the prevalence of diseases such as cancer, diabetes, tumors, and prenatal genetic disorder followed by increasing research & development activity using single-cell genome sequencing will create the demand for single-cell genome sequencing. Therefore, it is anticipated to boost the global market for single-cell genome sequencing over the forecast period.
Further, rising focus on the product or drug development is a key factor fueling the overall market growth. In addition to this, government policies and their initiatives in advanced science are expected to propel the growth of the global single-cell genome sequencing market during the forecast period.
High cost and analytical challenges
However, high cost and analytical challenges in the quantity of the single cell could turn out to a growth barrier for the market of the single-cell genome sequencing within the forecast period.
Global SingleCell Genome Sequencing Market Segmentations & Regional Insights
The global single-cell genome sequencing market has been segmented on the basis of type, technology, application, end-user, and region. The type segment includes reagents and instruments. Further, the global single-cell genome sequencing market is segmented by technology, which includes NGS, PCR, qPCR, MDA, and Microarray.
On the basis of application, the global single-cell genome sequencing market is divided into circulating cells, genomic variation, cell differentiation, subpopulation characterization, and others.
On the basis of the end user, the global single-cell genome sequencing market is segmented into forensic labs, cell banks and IVF centers, academic & research laboratories, biotechnology & biopharmaceutical companies, and hospitals and diagnostic laboratories.
Regional Insights:
On the basis of region, the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific market is expected to observe the most elevated development during the conjecture time frame. The presence of a huge patient populace (particularly in China and India), expanding interests in R&D, and development in the re-appropriating of medication revelation administrations to Asian CROs are a portion of the central point driving the interest for single-cell examination consumables and instruments in this territorial market.
Report scope:
Attribute |
Details |
Market Size 2024 |
US$ 2.6 Billion |
Projected Market Size 2034 |
US$ 10.8 Billion |
CAGR Growth Rate |
16.9% |
Base year for estimation |
2023 |
Forecast period |
2024 – 2034 |
Market representation |
Revenue in USD Billion & CAGR from 2024 to 2034 |
Market Segmentation |
By Type: Reagents and Instruments By Technology: NGS, PCR, qPCR, MDA, and Microarray By Application: Circulating Cells, Genomic Variation, Cell Differentiation, Subpopulation Characterization, and Others By End-User: Forensic Labs, Cell banks and IVF centers, Academic & Research Laboratories, Biotechnology & biopharmaceutical companies, and Hospitals and diagnostic laboratories |
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global Automated Border Control market report based on type, technology, application, end-user and region.
Single Cell Genomics Sequencing Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
-
- U.S.
- Canada
- Middle East & Africa
Global SingleCell Genome Sequencing Market Competitive Landscape & Key Players
Key players operating in the single-cell genome sequencing include ThermoFisher Scientific, Inc., Illumina, Bio-Rad, BD, Pacific Biosciences of California, Inc., QIAGEN, 10X Genomics, Inc., BGI, Novogene Co. Ltd., NuGEN Technologies, Inc., Takara Bio, Inc., F Hoffmann-La Roche Ltd., Oxford Nanopore Technologies, Fludigim, and Agilent Technologies Inc.
Global SingleCell Genome Sequencing Market Company Profile
- ThermoFisher Scientific, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Illumina
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Bio-Rad
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- BD
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Pacific Biosciences of California, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- QIAGEN
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- 10X Genomics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- BGI
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Novogene Co. Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- NuGEN Technologies, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Takara Bio, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
Global SingleCell Genome Sequencing Market Highlights
FAQs
The global single-cell genome sequencing market has been segmented on the basis of type, technology, application, end-user, and region.
The prevalence of diseases such as cancer, diabetes, tumors, and prenatal genetic disorder followed by increasing research & development activity using single-cell genome sequencing will create the demand for single-cell genome sequencing. Therefore, it is anticipated to boost the global market for single-cell genome sequencing over the forecast period.
North America is expected to account major market share as compared to that of other regions.
Key players operating in the global market of single-cell genome sequencing include ThermoFisher Scientific, Inc., Illumina, Bio-Rad, BD, Pacific Biosciences of California, Inc., QIAGEN, 10X Genomics, Inc., BGI, Novogene Co. Ltd., NuGEN Technologies, Inc., Takara Bio, Inc., F Hoffmann-La Roche Ltd., Oxford Nanopore Technologies, Fludigim, and Agilent Technologies Inc.